BioNTech SE agreed to buy former Covid vaccine rival CureVac NV for about $1.25 billion in an all-stock transaction that will boost its growing oncology business.
www.bloomberg.com
#BioNTech #Buy #CureVac #Billion #Boost #Cancer #Arm
Fifth Avenue watch and jewelry emporium Wempe will more than double the size of its Patek Philippe boutique as Rolex…
Unlock the Editor’s Digest for free Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.…
The state again looks to cut incentives for home users in a push to curb soaring electricity rates. www.bloomberg.com #Californias #Rooftop #Solar #Dreams…
